Mattias J. Johansson - Epidemiology

Author Information

Mattias Johansson is a prominent researcher affiliated with the Genetic Epidemiology Group (GEP) at the International Agency for Research on Cancer (IARC) in Lyon, France. His work primarily focuses on the epidemiology of cancer, with a particular interest in genetic and biomarker studies to understand cancer etiology and risk factors.

Research Contributions

In 2022 alone, Mattias Johansson has contributed to a diverse array of studies, including investigations into the relationship between physical activity and mortality, blood metabolite concentrations in cancer, and the role of blood pressure in renal cell carcinoma risk. His research spans multiple cancer types and methodologies, such as Mendelian randomization analyses and genome-wide interaction studies. Notable works include studies on the connection between circulating inflammatory cytokines and cancer risk, as well as the identification of biomarkers relevant to lung cancer survival and renal cell carcinoma.

Aliases

M. Johansson is also known by several aliases, including M Johansson, Mattias J. Johansson, and Mattias Johansson.

Publication and Citation Metrics

Metric	Value
Citation Count	24,799
H-index	62
Paper Count	328

Publications:

Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: the European Prospective Investigation into Cancer and Nutrition

DOI:

Year: 2022

Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition

DOI: 10.1101/2022.04.11.22273693

Year: 2022

The relationship between blood pressure and risk of renal cell carcinoma.

DOI: 10.1093/ije/dyac042

Year: 2022

Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis

DOI: 10.1186/s12916-021-02193-0

Year: 2022

Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis.

DOI: 10.1016/j.canep.2022.102117

Year: 2022

Prediagnosis Leisure-Time Physical Activity and Lung Cancer Survival: A Pooled Analysis of 11 Cohorts

DOI: 10.1093/jncics/pkac009

Year: 2022

Body size at different ages and risk of six cancers: a Mendelian randomization and prospective cohort study.

DOI: 10.1093/jnci/djac061

Year: 2022

Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk.

DOI: 10.1093/hmg/ddac030

Year: 2022

Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

DOI: 10.1101/2022.03.21.22272544

Year: 2022

Biomarkers of the transsulfuration pathway and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.

DOI: 10.1002/ijc.34009

Year: 2022

Why is Legal Enforcement Necessary?

What is Genomic DNA?

What are the Applications of Molecular Pathology in Epidemiology?

Who are Indigenous Populations?

What are Interferon Gamma Release Assays (IGRAs)?

Why are Testing Sites Important in Epidemiology?

Why are Objective Lenses Important in Epidemiology?

What Role Does Data Analytics Play in Modern Epidemiology?

What Impact Does the Flipped Classroom Have on Learning Outcomes?

How Do GAMs Work?

Partnered Content Networks

Relevant Topics